Tilray Is Down 57% in 2026. Here's What History Says About Buying Pot Stocks at the Bottom

Tilray Brands shares are down 57% year-to-date and have lost more than 90% of their value since early 2021, while an S&P 500 ETF would have more than doubled investor capital over that period. U.S. movement of certain medical cannabis products from Schedule I to Schedule III could reduce costs and expand research opportunities, but federal restrictions, potential competition and Canada's weak legalization outcome limit the upside. The article concludes that Tilray's mediocre financial results and uncertain regulatory environment leave little basis for a sustained rebound.

Analysis

TLRY’s central problem is not demand optionality but monetization quality: any U.S. regulatory catalyst is likely to rerate licensed, state-level operators with existing dispensary, cultivation, and medical-market footprints before it benefits a Canadian operator with indirect U.S. exposure. Beverage distribution is strategically useful only if federal rules permit a scalable THC product architecture; it does not overcome state-by-state licensing, formulation, and interstate-commerce constraints. The more immediate second-order winner from tax reform would be U.S. plant-touching MSOs, where removal of punitive tax treatment could convert reported losses into materially higher free cash flow; TLRY’s benefit is comparatively less direct.

Over the next days to three months, TLRY remains highly exposed to retail-flow and regulatory headlines rather than an earnings-driven valuation floor. A durable long case requires independently verifiable evidence of improved operating cash flow, stabilization in share count/net dilution, and beverage profitability sufficient to fund cannabis optionality without repeated equity issuance. Over 6-18 months, broad legalization could be a mixed outcome: it expands TAM but lowers barriers to entry for alcohol, tobacco, consumer packaged goods, and well-capitalized MSOs, likely compressing commodity cannabis economics. The contrarian point is that bearish sentiment can produce sharp squeezes on a definitive federal milestone, but such rallies should be sold unless accompanied by a credible route to U.S. plant-touching economics.

The key falsifiers for a cautious view are two consecutive quarters of positive operating cash flow excluding working-capital benefits, no material increase in diluted shares, and a regulatory framework that explicitly enables interstate commerce or federally compliant THC beverage distribution. Conversely, renewed cash burn, impairment charges, or another capital raise would validate a lower-multiple/dilution thesis even if sector sentiment improves.

Key Decisions for Investors

• No outright TLRY long ahead of headline-driven regulatory events; treat it as a watchlist volatility instrument, not a fundamental compounder. Reassess only after the next two earnings releases show operating-cash-flow improvement and diluted-share stabilization.
• For a regulatory-tax catalyst, prefer a basket long of U.S. MSO exposure through MSOS rather than TLRY, sized for binary policy risk over a 3-6 month horizon. The thesis is falsified if implementation language excludes ordinary-business-expense relief or if state-level pricing pressure offsets the tax benefit.
• Relative-value expression: long MSOS / short TLRY in equal beta-adjusted notional for 3-6 months. This isolates the expected advantage of direct U.S. plant-touching exposure over TLRY’s indirect optionality; cover if TLRY announces an accretive, financed U.S. operating entry or the spread widens materially without a policy catalyst.
• If a formal federal action produces a retail-driven TLRY spike without corresponding guidance on U.S. revenue, cash flow, or capital needs, use strength to initiate a small tactical short or buy put spreads with 1-3 month tenor. Risk is a short squeeze from retail positioning or a surprise strategic transaction; cap loss through defined-risk options.